Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 25Lymphoma 21Neutropenia 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Carcinoma, Non-Small-Cell Lung 8Multiple Myeloma 7Leukemia 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Urinary Bladder Neoplasms 4Testicular Neoplasms 4Sarcoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Hodgkin Disease 4Central Nervous System Neoplasms 4Testicular Germ Cell Tumor 3Teratoma 3Rhabdomyosarcoma 3Chemotherapy-induced Neutropenia 3Carcinoma, Ovarian Epithelial 3Carcinoma, Embryonal 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

ibrutinib 3ruxolitinib 2asciminib 2Alemtuzumab 2sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1ofatumumab 1nilotinib 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1bosutinib 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Saline Solution 1SLC25A33 protein, human 1Rituximab 1Ribavirin 1Respiratory Function Tests 1Prednisone 1Pentostatin 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bronchiolitis Obliterans Syndrome × pegfilgrastim × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡